Implantable glucose sensor market seen reaching $16.05 billion by 2030

The Business Research Company says the implantable glucose sensor market is poised to rise from $8.14 billion in 2025 to $16.05 billion by 2030 as diabetes cases climb and continuous monitoring gains traction. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Implantable glucose sensors are gaining traction because they can reduce finger-prick testing and provide continuous blood sugar data. - The market outlook points to strong demand for longer-term glucose monitoring, better diabetes management and wider use of connected health tools. - Growth in the market tracks with rising diabetes and prediabetes cases worldwide.

What happened: - The Business Research Company released a market outlook on the implantable glucose sensor market on August 11, 2026, in London. - The report estimates the market will increase from $8.14 billion in 2025 to $9.34 billion in 2026. - The report forecasts the market will reach $16.05 billion by 2030. - The report projects a 14.7% CAGR for 2025-2026 and a 14.5% CAGR for 2026-2030. - A free sample of the report is available here. - The full report is available here.

The details: - An implantable glucose sensor is a device placed under the skin to monitor glucose levels continuously and send readings to an external monitor or smart device. - The technology is designed to cut reliance on frequent finger-prick tests. - The report says earlier growth was driven by rising diabetes prevalence, limits of traditional finger-stick testing, early adoption of continuous glucose monitoring, higher healthcare spending and better sensor accuracy. - Future growth is tied to long-term glucose monitoring, integration with insulin delivery systems, a larger diabetic population, sensor miniaturization and favorable reimbursement policies. - Emerging trends include extended-duration implantable sensors, finger-prick-free diabetes management, biocompatible sensor materials, real-time continuous glucose tracking and more home-based monitoring. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis.

Between the lines: - The forecast reflects a broader shift toward diabetes tools that automate monitoring and improve convenience for patients. - The growth assumptions suggest reimbursement and device integration could matter as much as sensor performance. - The regional split points to mature adoption in North America and faster expansion in markets still building access and awareness. - In June 2024, the UK National Health Service reported 3,615,330 people with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in 2022.

What's next: - The market is expected to keep expanding through 2030 as more patients, providers and payers adopt continuous glucose monitoring. - Product development is likely to focus on longer wear times, smaller sensors and better compatibility with insulin delivery systems. - Adoption could accelerate if reimbursement stays supportive and home monitoring continues to gain acceptance.

The bottom line: - Implantable glucose sensors are moving from a niche diabetes tool toward a larger monitoring market, with growth shaped by rising disease burden and demand for easier, more continuous care.